Harold J. Burstein, MD, PhD, joins the Oncology Brothers, Rahul Gosain, MD, and Rohit Gosain, MD, to provide clinical insights on treatment practices for patients with early-stage HER2+ breast cancer.
Japan’s MHLW Receives sNDA For T-DXd Combo in Frontline HER2+ Breast Cancer
Data from the phase 3 DESTINY-Breast09 trial presented at the 2025 ASCO Annual Meeting formed the basis of the supplemental NDA.
Cardiovascular Considerations in Breast Cancer Treatment and Survivorship
Up-front risk stratification for additional cardiovascular testing may help mitigate cardiovascular toxicities in breast cancer treatment.
Cryoablation Regimen Receives FDA Marketing Authorization for Breast Cancer
Cryoablation, when combined with adjuvant endocrine therapy, may offer a minimally invasive outpatient strategy in older patients with breast cancer.
Advancements and Evolving Strategies in Breast Cancer Treatment at IBC East
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Trastuzumab Deruxtecan Regimen Accepted for Review in HER2+ Breast Cancer
The decision is based on phase 3 DESTINY-Breast11 trial data, in which the investigational regimen displayed improved pCR vs SOC in this breast cancer population.
FDA Grants Fast Track Designation to Novel PIK3α Inhibitor in Breast Cancer
Combination therapy of ETX-636 plus fulvestrant is being administered to patients with HR–positive, HER2-negative breast cancer in a phase 1/2 trial.